Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Sita Awasthi"'
Autor:
Kevin P. Egan, Sita Awasthi, Giulia Tebaldi, Lauren M. Hook, Alexis M. Naughton, Bernard T. Fowler, Mitchell Beattie, Mohamad-Gabriel Alameh, Drew Weissman, Gary H. Cohen, Harvey M. Friedman
Publikováno v:
Viruses, Vol 15, Iss 7, p 1483 (2023)
HSV-1 disease is a significant public health burden causing orofacial, genital, cornea, and brain infection. We previously reported that a trivalent HSV-2 gC2, gD2, gE2 nucleoside-modified mRNA-lipid nanoparticle (LNP) vaccine provides excellent prot
Externí odkaz:
https://doaj.org/article/4ef81b6da24b4b0e90b0bd78a21e8ba3
Autor:
Sita Awasthi, Motoyasu Onishi, John M. Lubinski, Bernard T. Fowler, Alexis M. Naughton, Lauren M. Hook, Kevin P. Egan, Masaki Hagiwara, Seiki Shirai, Akiho Sakai, Takayuki Nakagawa, Kumiko Goto, Osamu Yoshida, Alisa J. Stephens, Grace Choi, Gary H. Cohen, Kazufumi Katayama, Harvey M. Friedman
Publikováno v:
Viruses, Vol 15, Iss 5, p 1148 (2023)
Herpes simplex virus type 2 (HSV-2) is a leading cause of genital ulcer disease and a major risk factor for acquisition and transmission of HIV. Frequent recurrent genital lesions and concerns about transmitting infection to intimate partners affect
Externí odkaz:
https://doaj.org/article/85b38cdef9e547f7a97265fe8e4bc36b
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 16, Iss 9, Pp 2109-2113 (2020)
A vaccine to prevent genital herpes is an unmet public health need. We previously reported that a trivalent vaccine containing herpes simplex virus type 2 (HSV-2) glycoproteins C, D, and E (gC2, gD2, gE2) produced in baculovirus and administered with
Externí odkaz:
https://doaj.org/article/702892be8062469c9d3fd63ef855aae9
Autor:
Lauren M. Hook, Sita Awasthi, Tina M. Cairns, Mohamad-Gabriel Alameh, Bernard T. Fowler, Kevin P. Egan, Molly M. H. Sung, Drew Weissman, Gary H. Cohen, Harvey M. Friedman
Publikováno v:
Viruses, Vol 14, Iss 3, p 540 (2022)
The toxicity of mRNA-lipid nanoparticle (LNP) vaccines depends on the total mRNA-LNP dose. We established that the maximum tolerated dose of our trivalent mRNA-LNP genital herpes vaccine was 10 μg/immunization in mice. We then evaluated one of the m
Externí odkaz:
https://doaj.org/article/76b703be13f248fdb48237fd38d0e99f
Autor:
Kevin P Egan, Lauren M Hook, Alexis Naughton, Norbert Pardi, Sita Awasthi, Gary H Cohen, Drew Weissman, Harvey M Friedman
Publikováno v:
PLoS Pathogens, Vol 16, Iss 7, p e1008795 (2020)
HSV-1 causes 50% of first-time genital herpes infections in resource-rich countries and affects 190 million people worldwide. A prophylactic herpes vaccine is needed to protect against genital infections by both HSV-1 and HSV-2. Previously our labora
Externí odkaz:
https://doaj.org/article/e0b8df62cbb540cb8a812e1925c3059e
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 13, Iss 12, Pp 2785-2793 (2017)
An estimated 417 million people worldwide ages 15 to 49 are infected with herpes simplex virus type 2 (HSV-2), the most common cause of genital ulcer disease. Some individuals experience frequent recurrences of genital lesions, while others only have
Externí odkaz:
https://doaj.org/article/d7afa5ba973f479baa583770f4f305fb
Autor:
Lauren M Hook, Tina M Cairns, Sita Awasthi, Benjamin D Brooks, Noah T Ditto, Roselyn J Eisenberg, Gary H Cohen, Harvey M Friedman
Publikováno v:
PLoS Pathogens, Vol 14, Iss 5, p e1007095 (2018)
Herpes simplex virus type 2 (HSV-2) glycoprotein D (gD2) subunit antigen is included in many preclinical candidate vaccines. The rationale for including gD2 is to produce antibodies that block crucial gD2 epitopes involved in virus entry and cell-to-
Externí odkaz:
https://doaj.org/article/94b16760525241f59e0e0ab677abcc95
Autor:
Sita Awasthi, Lauren M Hook, Carolyn E Shaw, Bapi Pahar, Jacob A Stagray, David Liu, Ronald S Veazey, Harvey M Friedman
Publikováno v:
PLoS Pathogens, Vol 13, Iss 1, p e1006141 (2017)
A genital herpes vaccine is urgently needed to prevent pain and suffering, reduce the incidence of neonatal herpes, and decrease the risk of HIV acquisition and transmission that accompanies genital infection. We evaluated a trivalent HSV-2 subunit a
Externí odkaz:
https://doaj.org/article/b13d3478ed1c440ab55d32d0d64002db
Autor:
Friedman, Kevin P. Egan, Sita Awasthi, Giulia Tebaldi, Lauren M. Hook, Alexis M. Naughton, Bernard T. Fowler, Mitchell Beattie, Mohamad-Gabriel Alameh, Drew Weissman, Gary H. Cohen, Harvey M.
Publikováno v:
Viruses; Volume 15; Issue 7; Pages: 1483
HSV-1 disease is a significant public health burden causing orofacial, genital, cornea, and brain infection. We previously reported that a trivalent HSV-2 gC2, gD2, gE2 nucleoside-modified mRNA-lipid nanoparticle (LNP) vaccine provides excellent prot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::47ff6684c4b9e307728489d54e5e5785
Autor:
Sita Awasthi, Harvey M. Friedman
Publikováno v:
Translational Research
The rapid development of 2 nucleoside-modified mRNA vaccines that are safe and highly effective against coronavirus disease 2019 has transformed the vaccine field. The mRNA technology has the advantage of accelerated immunogen discovery, induction of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92bb507bc686cbf1bc53fb52ccc45a52
https://doi.org/10.1016/j.trsl.2021.12.006
https://doi.org/10.1016/j.trsl.2021.12.006